Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D. to its board of directors effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees. Dr. Bertozzi is a Nobel Prize-winning chemist and currently serves as Baker Family director of Sarafan ChEM-H and professor at Stanford, and is an Investigator of the Howard Hughes Medical Institute.

Dr. Bertozzi previously served on Lilly's board from 2017 to 2021 and is an elected member of the National Academy of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences.

Lilly (NYSE: LLY) announced Phase 3 BRUIN CLL-314 results showing Jaypirca (pirtobrutinib) met the primary endpoint of non-inferiority for overall response rate (ORR) versus Imbruvica (ibrutinib) in CLL/SLL (ITT ORR 87.0% vs 78.5%; nominal p=0.0035; 95% CIs reported).

PFS was immature but trended toward pirtobrutinib across populations (ITT HR=0.569) with a 76% reduction in risk of progression or death in the treatment-naïve subgroup (HR=0.239). Safety signals favored pirtobrutinib on atrial fibrillation/flutter (2.4% vs 13.5%) and hypertension (10.6% vs 15.1%). Data to be published in Journal of Clinical Oncology and presented at ASH 2025.

Eli Lilly (NYSE: LLY) announced that on December 3, 2025 the U.S. FDA approved an expanded indication for Jaypirca (pirtobrutinib) to treat adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor.

The action converts Jaypirca's December 2023 accelerated approval to a traditional approval and is based on results from the BRUIN CLL-321 randomized Phase 3 trial. Jaypirca is described as the first and only FDA-approved non-covalent (reversible) BTK inhibitor and the label expansion aligns with NCCN guideline patient population recommendations.

Eli Lilly (NYSE: LLY) will present updated clinical and translational data at the San Antonio Breast Cancer Symposium, Dec 9–12, 2025, across hormone receptor–positive, HER2– breast cancer programs.

Highlights include a late-breaking oral presentation of Phase 3 EMBER-3 results for Inluriyo (imlunestrant) ± Verzenio (abemaciclib) with an interim overall survival analysis and updates on PFS and time to chemotherapy, updated ctDNA exploratory analyses, a monarchE nodal-status subgroup analysis for adjuvant abemaciclib, and Phase 1/2 PIKALO-1 results for LY4064809 ahead of Phase 3 PIKALO-2.

Eli Lilly (NYSE: LLY) will present multiple clinical results for Jaypirca (pirtobrutinib) at the 67th ASH Annual Meeting, Dec 6-9, 2025 in Orlando.

Key highlights: BRUIN CLL-314 (head-to-head vs ibrutinib) is reported to have met its primary endpoint of response-rate non-inferiority, favoring pirtobrutinib with a nominal P-value < 0.05 and will be an oral presentation on Dec 7. BRUIN CLL-313 (vs chemoimmunotherapy in treatment‑naïve CLL/SLL without del(17p)) met its primary endpoint with a highly statistically significant and clinically meaningful PFS benefit and is a late‑breaking oral presentation on Dec 8.

Additional oral and poster presentations include ~5‑year follow-up Phase 1/2 BRUIN data and investigator-led combination and disease‑specific studies.

Eli Lilly (NYSE: LLY) announced plans to open a new Lilly Gateway Labs site in Philadelphia on Nov. 19, 2025, expanding its U.S. footprint to four centers (Boston, South San Francisco, San Diego, Philadelphia).

The Philadelphia site will occupy 44,000 square feet at 2300 Market, a life sciences facility developed and operated by Breakthrough Properties, and will offer dedicated wet lab space and strategic scientific engagement for a select group of early-stage biotech companies.

Since the first Gateway Labs opened in 2019, resident companies have collectively raised more than $3 billion and advanced over 50 therapeutic programs. Gateway Labs is part of Lilly Catalyze360 alongside Lilly Ventures, ExploR&D and TuneLab.

Eli Lilly and Company (NYSE:LLY) will participate in Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will appear in a fireside chat at 10:30 a.m. ET.

A live audio webcast will be available in the Webcasts & Presentations section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations, and a replay will be accessible on the same page for approximately 90 days.

Lilly (NYSE:LLY) launched the Changing the Thread Collection in partnership with stylist Tan France to address obesity bias by using clothing as a canvas for stitched stories from people living with obesity.

The multichannel campaign connects science and storytelling to reframe obesity as a chronic disease and highlights Zepbound (tirzepatide) as a prescription treatment to help adults with obesity lose weight when used with diet and exercise. The collection includes everyday garments embroidered with personal narratives and links to an immersive site at ChangingTheThreadCollection.com. A public event is scheduled for Nov 14–15, 2025 in New York City at 13 Crosby Street.

Eli Lilly (NYSE: LLY) on November 6, 2025 announced two new Executive Committee appointments and broader leadership role expansions to support its pipeline, portfolio growth, and patient access.

Carole Ho, M.D. joins as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Adrienne Brown is promoted to executive vice president and president, Lilly Immunology, and will join the Executive Committee. Daniel Skovronsky, M.D., Ph.D. takes an expanded role as chief scientific and product officer and president, Lilly Research Laboratories. Jacob Van Naarden will lead corporate business development in addition to oncology.